TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pharmacokinetics
Research from University of Cape Town provides new data on pharmacokinetics
March 18th, 2008
According to recent research published in the Journal of Antimicrobial Chemotherapy, "Nevirapine-containing antiretroviral therapy (ART) and rifampicin-based antitubercular therapy are commonly co-administered in Africa, where nevirapine is often the only available non-nucleoside reverse transcriptase inhibitor. Rifampicin induces the metabolism of nevirapine, but the extent of the reduction in nevirapine concentrations has varied widely in previous studies." "We describe the steady-state pharmacokinetics of nevirapine during and after antitubercular therapy in South African patients. Sixteen patients receiving ART including standard doses of nevirapine were...
Source: TB & Outbreaks Week (2008-03-18)
|
